Porcine brain-derived peptide preparation

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain; the app lists a half-life of 30 minutes, and none of the sources read gives one.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Cerebrolysin after one dose: 50% at ~30 min, 25% at 60 min, 12.5% at 90 min.

Drawn from the half-life in the app's model, ~30 min. The model's figures

Cerebrolysin is described in the 2023 Cochrane review of its use in acute ischaemic stroke as a mixture of low-molecular-weight peptides and amino acids derived from porcine brain.1 The manufacturer's prescribing information summary, which states that it is based on the Austrian summary of product characteristics, names EVER Neuro Pharma GmbH as marketing authorisation holder.2 It lists the indications as senile dementia of Alzheimer’s type, vascular dementia, stroke and craniocerebral trauma, gives the concentration as 215.2 mg of concentrate per mL, and states that the product is available only on prescription and in pharmacies.2 The manufacturer's notice to US visitors states that Cerebrolysin "is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States".3 The app grades the evidence for Cerebrolysin as moderate. The registry entries for two of the trials described below, CASTA and CAPTAIN, name Ever Neuro Pharma GmbH, the marketing authorisation holder, as lead sponsor.4,5

The mechanism material on Cerebrolysin in the sources comes from laboratory and animal work, and the PubMed records of the CASTA, CAPTAIN I, CAPTAIN II, Alvarez and Funke trials report clinical, cognitive or EEG outcomes and no mechanistic biomarkers. Masliah and Díez-Tejedor, in a 2012 review in Drugs of Today, write that Cerebrolysin "mimics the action of endogenous neurotrophic factors on brain protection and repair" and that their section summarises data "obtained from in vitro assays (biochemical and cell cultures) and in vivo animal models of acute and chronic neurological disorders".6 In stroke animal models the review reports that Cerebrolysin "stabilizes the structural integrity of cells by inhibition of calpain and reduces the number of apoptotic cells after ischemic lesion".6 The manufacturer's mode of action page says Cerebrolysin "has shown to modify two major signalling pathways: the neurotrophic factor (NTF) and sonic hedgehog (Shh) signalling pathway".7 For the distribution of radiolabelled peptides in the central nervous system, that page cites a study listed as "not published, 2004".7 Plosker and Gauthier, in a 2009 review in Drugs & Aging, describe Cerebrolysin as a "parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors".8

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~30 min
Bioavailability
100%
Typical dose
5–30 mL/day
Route
IM
Time to peak
~30 min

The app's figures are a half-life of 0.5 hours, bioavailability of 100%, a time to peak of 0.5 hours, a duration of 3 hours and intramuscular administration. No half-life, bioavailability or time-to-peak figure for Cerebrolysin was identified in the sources read, and the manufacturer's summary refers pharmacokinetic properties to the summary of product characteristics, which was not among them.2

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~30 min (0.5 h)None identified in the sources read; the manufacturer's summary refers to the summary of product characteristics for pharmacokinetic properties2
Bioavailability100%None identified in the sources read; the three trials cited here gave Cerebrolysin by intravenous infusion rather than by intramuscular injection4,5,9
Time to peak~30 min (0.5 h)None identified in the sources read2
Duration~3 hNone identified; in a healthy-volunteer study, an EEG power ratio effect in the 10 mL group "started after 15 min, was most expressed at 2 h and was kept until 8 h", which is an EEG effect and not a drug concentration10
RouteIMThe trials read gave Cerebrolysin by intravenous infusion: 30 mL daily for 10 days in CASTA, 50 mL daily for 10 days in CAPTAIN, and 10, 30 or 60 mL in the Alzheimer's dose-ranging trial4,5,9

The chart applies the app's figures to the once-daily, 10-day interval in the CASTA registry entry (intravenous infusion) and is not a measured concentration.4

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once daily for 10 days (CASTA, intravenous infusion)4.

An illustration from a pharmacokinetic model using a half-life of 0.5 hours. It is not a measured level or a suggested dose.

4

Human studies

The studies read cover acute ischaemic stroke, traumatic brain injury, Alzheimer's disease and vascular dementia; for most trials only the PubMed record was read.

Table 4.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Heiss and colleagues (CASTA), Stroke 201211Randomised, double-blind, placebo-controlled; registry names Ever Neuro Pharma GmbH as lead sponsor41070 patients with acute ischemic hemispheric stroke (529 Cerebrolysin, 541 placebo)30 mL Cerebrolysin or saline daily by intravenous infusion for 10 days plus aspirin 100 mg daily; followed to 90 daysConfirmatory end point showed no significant difference; post hoc severe subgroup showed a trend favouring Cerebrolysin
Ziganshina and colleagues, Cochrane Database of Systematic Reviews 20231Systematic review of randomised trials of Cerebrolysin or Cerebrolysin-like agents started within 48 hours of stroke7 trials, 1773 participants, including one Cortexin trial of 27210, 30 and 50 mL; 10 days to four weeksAll-cause death RR 0.96 (95% CI 0.65 to 1.41; 6 trials, 1689 participants, Cerebrolysin or Cortexin); non-fatal serious adverse events RR 2.39 (95% CI 1.10 to 5.23)
Poon and colleagues (CAPTAIN I), Neurological Sciences 202012Randomised, double-blind, placebo-controlled, multicentre; registry names Ever Neuro Pharma GmbH as lead sponsor and the trial as terminated for poor recruitment546 patients after moderate-to-severe traumatic brain injury (22 Cerebrolysin, 24 placebo)50 mL daily for 10 days, then two cycles of 10 mL daily for 10 days, plus standard carePrimary multivariate ensemble just missed significance in the intention-to-treat population; per-protocol analysis showed significant superiority of Cerebrolysin
Muresanu and colleagues (CAPTAIN II), Neurological Sciences 202013Single-centre, randomised, double-blind, placebo-controlled142 enrolled, 139 analysed, Glasgow Coma Score 7 to 1250 mL daily for 10 days, then two cycles of 10 mL daily for 10 days, plus standard carePrimary ensemble significant at day 90 (MWcombined 0.59, 95% CI 0.52 to 0.66, P = 0.0119); safety comparable between groups
Vester and colleagues, Neurological Sciences 202114Prospective meta-analysis of the two CAPTAIN trials185 patients, Glasgow Coma Score 6 to 1250 mL daily for 10 days, then two cycles of 10 mL daily for 10 daysDay 30 MWcombined 0.60 (95% CI 0.52 to 0.66, p = 0.0156); Day 90 MWcombined 0.60 (95% CI 0.52 to 0.68, p = 0.0146)
Alvarez and colleagues, European Journal of Neurology 20069Randomised, double-blind, placebo-controlled, four groups279 patients with mild to moderate Alzheimer's disease10, 30 or 60 mL intravenous infusions or placebo, 5 days a week for 4 weeks, then twice a week for 8 weeks; 24 weeksAt week 24, ADAS-cog improved with 10 mL (P=0.038); 30 and 60 mL improved global outcome but not cognition
Gauthier and colleagues, Dementia and Geriatric Cognitive Disorders 201515Meta-analysis of randomised, double-blind, placebo-controlled trials6 trials in mild-to-moderate Alzheimer's disease30 mL/day CerebrolysinCognition SMD -0.40 at 4 weeks (p = 0.0031) and -0.37 at 6 months (p = 0.1710); global clinical change OR 3.32 at 4 weeks and 4.98 at 6 months
Cui and colleagues, Cochrane Database of Systematic Reviews 201916Systematic review of randomised trials in vascular dementia6 trials, 597 participantsVarying doses and durations; follow-up 15 days to three yearsCognition SMD 0.36 (95% CI 0.13 to 0.58; very low-quality evidence); adverse effects RR 0.91 (95% CI 0.29 to 2.85; very low-quality evidence)

Deeper analysis: CASTA (acute ischemic stroke)

Heiss and colleagues, from the Max-Planck Institut für Neurologie in Cologne and the CASTA investigators, reported the trial in Stroke in 2012.11 Patients with acute ischemic hemispheric stroke were randomised within 12 hours of symptom onset to 30 mL Cerebrolysin daily or saline by intravenous infusion for 10 days, in addition to aspirin 100 mg daily, and were followed up to 90 days.11 Of 1070 patients, 529 were assigned to Cerebrolysin and 541 to placebo, and the authors state that the confirmatory end point "showed no significant difference between the treatment groups".11 A post hoc analysis stratified by severity "showed a trend in favor of Cerebrolysin" in patients with a baseline NIHSS above 12, with odds ratios of 1.27 on both the NIHSS and the modified Rankin Scale and confidence-interval lower bounds of 0.97 and 0.90.11 In that subgroup the cumulative 90-day mortality was 20.2% with placebo and 10.5% with Cerebrolysin, with a hazard ratio of 1.9661 and a confidence-interval lower bound of 1.0013.11 The Cochrane review of acute ischaemic stroke reports that the CASTA authors declared 28 deaths in the Cerebrolysin group and 32 in the placebo group overall (hazard ratio 1.26, probability 0.19), and that among the remaining 815 participants with a baseline NIHSS of 12 or below, 16 Cerebrolysin and 10 placebo participants died.1 The authors conclude that the confirmatory end point "showed neutral results between the treatment groups" and that the severe-subgroup observation needs confirmation in a further clinical trial.11 The PubMed record carries no funding statement; the registry entry names Ever Neuro Pharma GmbH as lead sponsor, Excel PharmaStudies, Inc. and idv Datenanalyse und Versuchsplanung as collaborators, and a study director from EVER Neuro Pharma.4 In the Cochrane review's reply to correspondence, its authors list Wolf Dieter Heiss as having "served on the Advisory Board and Speakers bureau for EVER Neuro Pharma".1

Deeper analysis: the Cochrane review of Cerebrolysin in acute ischaemic stroke

Ziganshina and colleagues (Russian Medical Academy of Continuing Professional Education and Kazan universities) included randomised trials of Cerebrolysin or Cerebrolysin-like agents started within 48 hours of stroke onset, and seven trials with 1773 participants met the criteria.1 The review reports "little to no difference" in all-cause death for Cerebrolysin or Cortexin (RR 0.96, 95% CI 0.65 to 1.41; moderate-certainty evidence), where Cortexin is a Cerebrolysin-like agent from cattle and pig brain that contributed one trial of 272 participants.1 For Cerebrolysin, total serious adverse events differed little (RR 1.16, 95% CI 0.81 to 1.66; 3 trials, 1335 participants), but non-fatal serious adverse events rose (RR 2.39, 95% CI 1.10 to 5.23), and in the 30 mL for 10 days subgroup the increase was larger (RR 2.87, 95% CI 1.24 to 6.69; 2 trials, 1189 participants).1 The authors state that the manufacturer "supported three multicentre studies, either totally, or by providing Cerebrolysin and placebo, randomisation codes, research grants, or statisticians", and they rate incomplete outcome data as high risk of bias in four of the seven studies.1 They name as a limitation that "reporting of data on death and safety parameters without clarification of the time of death or the time of development of adverse events, and the loss of data for many enrolled participants owing to attrition, hampered meaningful interpretation".1 The review lists no external funding, and one author's declaration notes she is a Cochrane director who was not involved in the editorial process.1

Deeper analysis: CAPTAIN I, CAPTAIN II and the combined analysis (traumatic brain injury)

Poon and colleagues, from the Prince of Wales Hospital, The Chinese University of Hong Kong, reported CAPTAIN I in Neurological Sciences in 2020.12 It randomised 46 patients (22 Cerebrolysin, 24 placebo) after moderate-to-severe traumatic brain injury, and its primary endpoint was "a multidimensional ensemble of 14 outcome scales" analysed by the Wei-Lachin procedure.12 Three single outcomes (Stroop Word/Dots Interference and Color Trails Tests 1 and 2) showed stand-alone superiority of Cerebrolysin, while the primary ensemble's significance "was just missed in the intention-to-treat population".12 The per-protocol analysis reached significance (pWei-Lachin = 0.0240, MWcombined 0.69, 95% CI 0.53 to 0.85), and the authors write that "Safety aspects were comparable to placebo" and call for confirmation in "a larger RCT with a comparable multidimensional approach".12 The registry entry lists the trial as terminated, with the reason "Poor patient recruitment", names Ever Neuro Pharma GmbH as lead sponsor, and describes quadruple masking.5 The Cochrane review's reply to correspondence lists Volker Homberg as "a member of the CAPTAIN trial scientific advisory board" and Johannes C. Vester as "a senior biometric consultant of IDV (Advisory Board for EVER Neuro Pharma)"; both are authors of the CAPTAIN papers.1 The same reply lists Dafin Fior Muresanu, an author of CAPTAIN I, CAPTAIN II and the pooled analysis, as a member of the CAPTAIN trial scientific advisory board who reports receipt of grants or research support from EVER Neuro Pharma.1 Muresanu and colleagues reported CAPTAIN II in Neurological Sciences in 2020, a single-centre trial that enrolled 142 patients, 139 of whom were analysed, with a mean age of 47.4 and a mean admission Glasgow Coma Score of 10.4.13 The primary endpoint, an ensemble of 13 outcome scales, was significant at day 90 (MWcombined = 0.59, 95% CI 0.52 to 0.66, P = 0.0119), and "Safety and tolerability observations were comparable between treatment groups".13 The PubMed record for CAPTAIN II carries no funding statement and its registry entry was not read; one author is affiliated with idv Data Analysis and Study Planning.13 Vester and colleagues pooled the two trials (185 patients) and report significance at Day 30 and Day 90, with comparable safety and tolerability between groups; the pooled estimates are labelled in the record as a "small-to-medium" sized effect.14 The PubMed record for the pooled analysis carries no funding statement; its first author Vester is described in the Cochrane review's reply as "a senior biometric consultant of IDV (Advisory Board for EVER Neuro Pharma)".14,1

Deeper analysis: Alzheimer's disease and vascular dementia

Alvarez and colleagues, from the Euroespes Biomedical Research Centre in Spain, reported a 24-week, four-group trial in the European Journal of Neurology in 2006, enrolling 279 patients with mild to moderate Alzheimer's disease (69 on 10 mL, 70 on 30 mL, 71 on 60 mL and 69 on placebo).9 At week 24, the 10 mL dose showed "significant improvement of cognitive performance on the ADAS-cog (P=0.038)", whereas the 30 and 60 mL doses "failed to show significant improvement of cognition" while improving global outcome.9 The authors report that "The percentage of patients reporting adverse events was similar across all study groups".9 The PubMed record gives no funding statement, author disclosures or stated limitations; its publication type includes "Research Support, Non-U.S. Gov't".9 Gauthier and colleagues pooled six placebo-controlled trials of 30 mL/day, stating their aim as "to avoid major deficiencies of an earlier meta-analysis".15 Cognition improved at 4 weeks (SMD -0.40, 95% CI -0.66 to -0.13; p = 0.0031) but the 6-month difference was not significant (SMD -0.37, 95% CI -0.90 to 0.16; p = 0.1710), while global clinical change favoured Cerebrolysin at both times (6 months: OR 4.98, 95% CI 1.37-18.13).15 The PubMed record names Vester JC, who also appears on the CAPTAIN papers, among the authors and gives no funding statement or stated limitations.15 Cui and colleagues, in a 2019 Cochrane review of vascular dementia from West China Hospital, Sichuan University, found six trials (597 participants) and report that "Where details of funding were available, all studies were supported by the pharmaceutical industry (three studies)".16 Its authors write that "these data are not definitive", that "the effects may be too small to be clinically meaningful" if there are benefits, and that "the supporting evidence base is weak".16

5

Doses reported in studies and on labels

The app lists a typical dose of 5 to 30 mL per day by the intramuscular route. The trials read used 10 to 60 mL per infusion by intravenous infusion, given daily for 10 days in CASTA and CAPTAIN and 5 days a week and then twice a week in the Alzheimer's dose-ranging trial, and the manufacturer's summary gives a concentration but no dose in the text read.

Table 5.1Doses reported in studies and on labels5 rows
SourcePopulation and nDose, route and durationComparator
CASTA registry entry and paper4,11Acute ischemic stroke, 1070 patients30 mL once daily by intravenous infusion for 10 consecutive daysSaline placebo; aspirin 100 mg daily in both groups
CAPTAIN I and II5,13Moderate-to-severe traumatic brain injury, 46 and 142 patientsPapers: 50 mL per day for 10 days, then two cycles of 10 mL per day for 10 days; registry (CAPTAIN I): intravenous infusion, 50 mL per day for 10 days, with the cycle repeated one and two months later if the extended Glasgow Outcome Scale score on Day 30 is below 7Saline placebo
Alvarez and colleagues9Mild to moderate Alzheimer's disease, 279 patients10, 30 or 60 mL by intravenous infusion, 5 days a week for 4 weeks, then twice a week for 8 weeksPlacebo (69 patients)
Funke and colleagues, healthy men1048 healthy males10, 30 or 50 mL in 100 mL saline by infusion for 10 days (route not further stated in the record)Saline (NaCl) placebo
Manufacturer's prescribing information summary2Not statedPosology and method of administration are referred to the summary of product characteristics; no dose appears in the text readNot applicable

Thome and Doppler, in a 2012 review in Drugs of Today, write that "adverse reactions to Cerebrolysin were generally mild and transient", with "vertigo, agitation and feeling hot" among the most common adverse events.17 They report that in the controlled trials analysed "the incidence of adverse events was similar in Cerebrolysin- and placebo-treated groups", and "to our knowledge" no major changes in vital signs or laboratory parameters were associated with it.17 The manufacturer's FAQ page states that "The most frequently reported adverse reactions with Cerebrolysin® are dizziness, headache, sweating, and nausea".18 In the Cochrane review of acute ischaemic stroke, total adverse events were similar (RR 1.03, 95% CI 0.92 to 1.14; low-certainty evidence), but non-fatal serious adverse events were higher with Cerebrolysin (RR 2.39, 95% CI 1.10 to 5.23; moderate-certainty evidence).1 In healthy men given 10, 30 or 50 mL for 10 days, the authors report that "Signs of overdosage occurred with the highest concentrations of Cerebrolysin", that the events "were only mild and caused no harm to the volunteers", and that the highest concentration "caused a small but significant reduction of blood pressure".10 On interactions, the manufacturer's FAQ page states that Cerebrolysin "is not approved for the treatment of depression" and that "possible additive effects have been observed when used in combination with anti-depressants or MAO inhibitors".18 The manufacturer's summary lists contraindications of "Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment".2

7

Bloodwork and markers

The app lists no health markers to monitor for Cerebrolysin. Thome and Doppler write that, to their knowledge, Cerebrolysin "was not associated with major changes in vital signs or laboratory parameters", and the healthy-volunteer study reported a small but significant blood pressure reduction at the highest dose.17,10 None of the sources read reports a laboratory marker used to follow Cerebrolysin exposure or response.

The manufacturer's notice to US visitors states that Cerebrolysin is not registered with the US Food and Drug Administration and is not approved for sale or distribution in the United States.3 The notice also describes Cerebrolysin as "a prescription medication for use under the supervision of an authorized health care professional".3 The manufacturer's prescribing information summary, based on the Austrian summary of product characteristics, gives the indication as "treatment of cerebrovascular disorders", especially senile dementia of Alzheimer’s type, vascular dementia, stroke and craniocerebral trauma.2 The manufacturer adds that the prescribing information in other countries may vary, and no European Medicines Agency or other regulator document for Cerebrolysin was read.2 The 2026 World Anti-Doping Agency Prohibited List text read does not name Cerebrolysin.19 Its class S2 for peptide hormones, growth factors, related substances and mimetics lists named examples under headings introduced with "Including, but not limited to:", so whether Cerebrolysin falls under an open wording of a class is not stated in the list text read.19

9

What is not known

  • No half-life, bioavailability, time-to-peak or intramuscular exposure figure for Cerebrolysin was identified in the sources read, so the app's figures of 0.5 hours, 100% and an intramuscular route have no figure from a source beside them.
  • The CASTA severe-subgroup result was post hoc, and its authors call for confirmation in a further trial.
  • The Cochrane review of acute ischaemic stroke found that none of the included studies reported poor functional outcome (defined as death or dependence at the end of the follow-up period), early death (within two weeks of stroke onset), quality of life, or time to restoration of capacity for work.
  • CAPTAIN I enrolled 46 patients and its authors call for a larger trial, and the CAPTAIN II authors suggest a large-scale observational study of real-world use.
  • In vascular dementia the Cochrane authors describe the supporting evidence as weak, with high risk of bias in the included papers.
  • The only healthy-volunteer study read was a 1998 trial of 48 men that measured EEG power and short-term memory.
What is Cerebrolysin made from?

It is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain.1

What is the half-life of Cerebrolysin?

The app lists a half-life of 0.5 hours (30 minutes), and none of the sources read reports a half-life figure. The manufacturer's summary refers pharmacokinetic properties to the summary of product characteristics.2

Is Cerebrolysin approved by the FDA?

The manufacturer states that Cerebrolysin is not registered with the FDA and is not approved for sale or distribution in the United States.3

Is Cerebrolysin banned by WADA?

The 2026 WADA Prohibited List text read does not name Cerebrolysin.19 The list introduces its S2 examples with "Including, but not limited to:", and the list text does not say how an unnamed mixture is classed.19

What are the side effects of Cerebrolysin?

A 2012 review reports that adverse reactions "were generally mild and transient", with vertigo, agitation and feeling hot among the most common adverse events.17 The Cochrane review of acute ischaemic stroke reports higher non-fatal serious adverse events with Cerebrolysin (RR 2.39, 95% CI 1.10 to 5.23; moderate-certainty evidence) and little to no difference in total serious adverse events (RR 1.16, 95% CI 0.81 to 1.66).1

Did Cerebrolysin improve outcomes in acute stroke trials?

In CASTA (1070 patients), the confirmatory end point showed no significant difference between Cerebrolysin and placebo.11 The 2023 Cochrane review found little to no difference in all-cause death (RR 0.96, 95% CI 0.65 to 1.41; Cerebrolysin or Cortexin), and the review states that the manufacturer supported three of the multicentre studies.1

Has Cerebrolysin been studied after traumatic brain injury?

Two randomised, placebo-controlled trials, CAPTAIN I (46 patients; primary ensemble just missed significance in the intention-to-treat population) and CAPTAIN II (142 enrolled), were pooled in a 2021 prospective meta-analysis of 185 patients that reported significance at Day 30 and Day 90; the registry entry for CAPTAIN I names Ever Neuro Pharma GmbH as lead sponsor, and the pooled analysis's first author is described in the Cochrane review's reply as a senior biometric consultant of IDV (Advisory Board for EVER Neuro Pharma).14,12,5,1

Has Cerebrolysin been studied in Alzheimer's disease?

A 2015 meta-analysis of six placebo-controlled trials of 30 mL/day in mild-to-moderate Alzheimer's disease reported cognition improved at 4 weeks (p = 0.0031) but not significantly at 6 months (p = 0.1710).15 A 279-patient trial of 10, 30 and 60 mL found a cognition benefit at week 24 only with the 10 mL dose (P=0.038).9

12

References

  1. Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev 2023;10:CD007026. Cochrane review 2023
  2. EVER Neuro Pharma GmbH. About Cerebrolysin (manufacturer web page with prescribing information summary), read 16 November 2026. Manufacturer overview page
  3. EVER Neuro Pharma GmbH. Adverse events (manufacturer web page with notice to US visitors), read 16 November 2026. Manufacturer adverse events page
  4. ClinicalTrials.gov. NCT00868283. The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke (CASTA). Sponsor: Ever Neuro Pharma GmbH. NCT00868283
  5. ClinicalTrials.gov. NCT01606111. The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery. Sponsor: Ever Neuro Pharma GmbH. NCT01606111
  6. Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin. Drugs Today (Barc) 2012;48 Suppl A:3-24. PMID 22514792
  7. EVER Neuro Pharma GmbH. Mode of action (manufacturer web page), read 16 November 2026. Manufacturer mode of action page
  8. Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging 2009;26(11):893-915. PMID 19848437
  9. Alvarez XA, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006;13(1):43-54. PMID 16420392
  10. Funke M, et al. Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. J Neural Transm Suppl 1998;53:385-98. PMID 9700674
  11. Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 2012;43(3):630-6. PMID 22282884
  12. Poon W, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I. Neurol Sci 2020;41(2):281-293. PMID 31494820
  13. Muresanu DF, et al. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci 2020;41(5):1171-1181. PMID 31897941
  14. Vester JC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci 2021;42(11):4531-4541. PMID 33620612
  15. Gauthier S, et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord 2015;39(5-6):332-47. PMID 25832905
  16. Cui S, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 2019;(11):CD008900. Cochrane review 2019
  17. Thome J, Doppler E. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. Drugs Today (Barc) 2012;48 Suppl A:63-9. PMID 22514795
  18. EVER Neuro Pharma GmbH. Frequently asked questions (manufacturer web page), read 16 November 2026. Manufacturer FAQ page
  19. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list 2026